Most comprehensive review to date discussing the role of C. pneumoniae in asthma, lung remodeling and COPD. Disease burden and societal costs of asthma and COPD are conventionally calculated as separate entities. If early treatment of C. pneumoniae (and/or other pathogens) benefits both asthma (by symptom control) and COPD (by interrupting pathogenesis), then benefit/cost ratios increase, perhaps dramatically.
This article explains how patients with pulmonary conditions are categorized in the US vs Europe. Copd, asthma, bronchitis, do you smoke? Are you older?